SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Antibody-drug conjugates--an emerging class of cancer treatmentBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaAntibody-drug conjugates as novel anti-cancer chemotherapeuticsCD19 as an attractive target for antibody-based therapyTargeting CD19 in B-cell lymphoma: emerging role of SAR3419Mechanisms of action of therapeutic antibodies for cancerNovel CD20 monoclonal antibodies for lymphoma therapyA human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaNature and importance of follicular lymphoma precursors.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodiesNatural compounds' activity against cancer stem-like or fast-cycling melanoma cells.Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxNative mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaOcular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical TrialsImmunotherapy in pediatric malignancies: current status and future perspectivesThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Methods for site-specific drug conjugation to antibodies.Advances in the treatment of hematologic malignancies using immunoconjugatesAntibody therapy for pediatric leukemia.B-cell-targeted therapies in systemic lupus erythematosusDesigning immunoconjugates for cancer therapy.Optimising the delivery of tubulin targeting agents through antibody conjugation.ADME of antibody-maytansinoid conjugatesTargeted drug delivery for cancer therapy: the other side of antibodies.Drug-conjugated antibodies for the treatment of cancer.CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Emerging drugs for acute lymphocytic leukemia.Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.Current status of antibody therapy in ALL.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.Novel approaches to pediatric leukemia treatment.Emerging immunological drugs for chronic lymphocytic leukemia.
P2860
Q24597424-A234CE62-C505-41B2-943E-5F31C61586B1Q26770312-C598B310-B978-47EA-A0ED-05C61385BAAAQ26785828-824E75BF-12D3-4081-8E07-D28788B79CEFQ26800175-0ACD0A66-7B23-4C76-B208-76EBC09D75DDQ27011836-07899619-F42C-4C3B-B6D1-0CDD08AF6147Q27027562-4D239887-456C-4E4A-B5B0-3EF3F9719957Q28385366-6EDCD7BE-B927-459D-BA50-C1CA4F6A3EEFQ28390112-4244C6BC-1DED-4DAF-8ED8-03757CD035C0Q28487973-243CF2E3-1516-4C7E-AFE9-0BD07B346C52Q33558757-17B631C6-4CF5-43C7-83F8-80ACB7131FEEQ34598149-18D389B3-0562-417A-A9E0-125D26FCE907Q35111429-F1E8BFD1-D521-4B44-9AD7-15625DE2A1A9Q35307091-BD7DDC04-0B85-4B4B-B0CF-BE964770C292Q35446035-6888DB7E-D156-4C58-90A0-A017FCEFA64CQ35946005-8F790862-57BF-49FA-B895-E06E8B0820F2Q36339717-A5EA923A-44E6-4DFA-9671-AFFEACBB01B2Q36366709-0F8B1149-DC6C-426B-85AE-DCE6CA7BA2D2Q36691818-EC1B80DE-2DE3-4B9F-ABBD-387B80A6BE63Q36745332-070ADC06-5212-4A98-980C-7104FDDB02EBQ37593707-10FD21E7-8B76-4990-957F-ED2A31F4EBFDQ37697843-929FC3F8-1B1E-49F4-8452-E3B5F523F2D8Q37725578-3B23AC83-F789-42FE-B426-29842E9E1FDAQ37729368-90F66267-5A89-401A-91CD-BA18E5C4AD53Q38017203-C486C36D-77A1-4A17-8D30-5FFABE435C81Q38024991-7E34D733-02B7-4234-B06C-844B30102660Q38033114-89499A2F-5E46-4A07-873D-2F7E73E1C614Q38058816-6F4DDBD5-92EA-404F-9E79-33F1E5ABF4FDQ38061647-8C2A8EFD-99EC-4EC0-8C60-BB2F186ED1AAQ38064963-0189B143-9267-4D0E-BDCA-72E581D3B678Q38068494-25938CC8-7CE1-480F-B062-513A40C3F142Q38092648-CD1B638A-8C4B-48D8-9A27-1A6F38EC912BQ38094099-C6EC34DB-C484-4DA9-9945-F511CDB0E5BDQ38097334-805B9F16-ABE4-4185-8503-1353A20A82BEQ38172586-CD12B367-8B8A-44A7-94C2-3A13D0337B21Q38202691-F9127941-8B1D-42E3-BD5F-61B7A623A478Q38224988-BB2238A6-6768-4788-9E25-DED8A30D9F47Q38266338-76D223AE-4176-43B8-B5BD-7D3003F9C2F1Q38312596-4EBEEA8F-6829-4808-BE14-89EA0D49A33CQ38500371-93568F97-BE6E-4DDE-8E22-A204F58A4200Q38543771-5EA20BA8-3588-4188-8CA5-705A09FE293D
P2860
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
SAR3419: an anti-CD19-Maytansi ...... atment of B-cell malignancies.
@en
SAR3419: an anti-CD19-Maytansi ...... atment of B-cell malignancies.
@nl
type
label
SAR3419: an anti-CD19-Maytansi ...... atment of B-cell malignancies.
@en
SAR3419: an anti-CD19-Maytansi ...... atment of B-cell malignancies.
@nl
prefLabel
SAR3419: an anti-CD19-Maytansi ...... atment of B-cell malignancies.
@en
SAR3419: an anti-CD19-Maytansi ...... atment of B-cell malignancies.
@nl
P2093
P1476
SAR3419: an anti-CD19-Maytansi ...... atment of B-cell malignancies.
@en
P2093
Anne Bousseau
Anne Caron
Chantal Carrez
John M Lambert
Robert J Lutz
Veronique Blanc
P304
P356
10.1158/1078-0432.CCR-11-0485
P407
P577
2011-10-01T00:00:00Z